Global Live Attenuated Influenza Vaccine (LAIV) Market Research Report 2026(Status and Outlook)
A Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" or "intranasal" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts.Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations.Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccine"s effectiveness is crucial in maintaining public confidence and its role in influenza prevention.Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccine"s effectiveness.Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use.
The global Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 8569.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.30% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Live Attenuated Influenza Vaccine (LAIV) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Live Attenuated Influenza Vaccine (LAIV) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Live Attenuated Influenza Vaccine (LAIV) market.
Global Live Attenuated Influenza Vaccine (LAIV) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Market Segmentation (by Type)
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Market Segmentation (by Application)
Hospital
Clinic
Public Health Agency
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Live Attenuated Influenza Vaccine (LAIV) Market
Overview of the regional outlook of the Live Attenuated Influenza Vaccine (LAIV) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine (LAIV) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine (LAIV), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 8569.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.30% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Live Attenuated Influenza Vaccine (LAIV) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Live Attenuated Influenza Vaccine (LAIV) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Live Attenuated Influenza Vaccine (LAIV) market.
Global Live Attenuated Influenza Vaccine (LAIV) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Market Segmentation (by Type)
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Market Segmentation (by Application)
Hospital
Clinic
Public Health Agency
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Live Attenuated Influenza Vaccine (LAIV) Market
Overview of the regional outlook of the Live Attenuated Influenza Vaccine (LAIV) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine (LAIV) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine (LAIV), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Live Attenuated Influenza Vaccine (LAIV)
1.2 Key Market Segments
1.2.1 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
1.2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Product Life Cycle
3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2020-2025)
3.4 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2020-2025)
3.5 Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends
3.8.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) INDUSTRY CHAIN ANALYSIS
4.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Live Attenuated Influenza Vaccine (LAIV) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Live Attenuated Influenza Vaccine (LAIV) Market
5.7 ESG Ratings of Leading Companies
6 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2020-2025)
6.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (2020-2025)
6.4 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2020-2025)
7 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Sales by Application (2020-2025)
7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Application (2020-2025)
7.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)
8 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SALES BY REGION
8.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region
8.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.3 North America
8.3.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.3.2 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.4.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.5.2 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.6.2 South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.7.2 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET PRODUCTION BY REGION
9.1 Global Production of Live Attenuated Influenza Vaccine (LAIV) by Region(2020-2025)
9.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2020-2025)
9.3 Global Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Live Attenuated Influenza Vaccine (LAIV) Production
9.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Live Attenuated Influenza Vaccine (LAIV) Production
9.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Live Attenuated Influenza Vaccine (LAIV) Production (2020-2025)
9.6.1 Japan Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.6.2 Japan Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Live Attenuated Influenza Vaccine (LAIV) Production (2020-2025)
9.7.1 China Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.7.2 China Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Sanofi Pasteur
10.1.1 Sanofi Pasteur Basic Information
10.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.1.4 Sanofi Pasteur Business Overview
10.1.5 Sanofi Pasteur SWOT Analysis
10.1.6 Sanofi Pasteur Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Basic Information
10.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 CSL
10.3.1 CSL Basic Information
10.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.3.4 CSL Business Overview
10.3.5 CSL SWOT Analysis
10.3.6 CSL Recent Developments
10.4 Abbott
10.4.1 Abbott Basic Information
10.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.4.4 Abbott Business Overview
10.4.5 Abbott Recent Developments
10.5 GlaxoSmithKline
10.5.1 GlaxoSmithKline Basic Information
10.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.5.4 GlaxoSmithKline Business Overview
10.5.5 GlaxoSmithKline Recent Developments
10.6 Serum Institute
10.6.1 Serum Institute Basic Information
10.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.6.4 Serum Institute Business Overview
10.6.5 Serum Institute Recent Developments
10.7 Fluenz Tetra
10.7.1 Fluenz Tetra Basic Information
10.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.7.4 Fluenz Tetra Business Overview
10.7.5 Fluenz Tetra Recent Developments
10.8 Cytiva
10.8.1 Cytiva Basic Information
10.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.8.4 Cytiva Business Overview
10.8.5 Cytiva Recent Developments
10.9 BioDiem
10.9.1 BioDiem Basic Information
10.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.9.4 BioDiem Business Overview
10.9.5 BioDiem Recent Developments
10.10 FluMist
10.10.1 FluMist Basic Information
10.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.10.4 FluMist Business Overview
10.10.5 FluMist Recent Developments
10.11 GSK
10.11.1 GSK Basic Information
10.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.11.4 GSK Business Overview
10.11.5 GSK Recent Developments
10.12 ChangChun High and New Technology
10.12.1 ChangChun High and New Technology Basic Information
10.12.2 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.12.3 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.12.4 ChangChun High and New Technology Business Overview
10.12.5 ChangChun High and New Technology Recent Developments
10.13 BCHT Biotechnology
10.13.1 BCHT Biotechnology Basic Information
10.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.13.4 BCHT Biotechnology Business Overview
10.13.5 BCHT Biotechnology Recent Developments
11 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET FORECAST BY REGION
11.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast
11.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region
11.2.4 South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Type (2026-2035)
12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Live Attenuated Influenza Vaccine (LAIV) by Type (2026-2035)
12.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Application (2026-2035)
12.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application
12.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Live Attenuated Influenza Vaccine (LAIV)
1.2 Key Market Segments
1.2.1 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
1.2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Product Life Cycle
3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2020-2025)
3.4 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2020-2025)
3.5 Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends
3.8.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) INDUSTRY CHAIN ANALYSIS
4.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Live Attenuated Influenza Vaccine (LAIV) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Live Attenuated Influenza Vaccine (LAIV) Market
5.7 ESG Ratings of Leading Companies
6 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2020-2025)
6.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (2020-2025)
6.4 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2020-2025)
7 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Sales by Application (2020-2025)
7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Application (2020-2025)
7.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)
8 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SALES BY REGION
8.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region
8.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.3 North America
8.3.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.3.2 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.4.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.5.2 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.6.2 South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.7.2 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET PRODUCTION BY REGION
9.1 Global Production of Live Attenuated Influenza Vaccine (LAIV) by Region(2020-2025)
9.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2020-2025)
9.3 Global Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Live Attenuated Influenza Vaccine (LAIV) Production
9.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Live Attenuated Influenza Vaccine (LAIV) Production
9.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Live Attenuated Influenza Vaccine (LAIV) Production (2020-2025)
9.6.1 Japan Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.6.2 Japan Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Live Attenuated Influenza Vaccine (LAIV) Production (2020-2025)
9.7.1 China Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)
9.7.2 China Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Sanofi Pasteur
10.1.1 Sanofi Pasteur Basic Information
10.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.1.4 Sanofi Pasteur Business Overview
10.1.5 Sanofi Pasteur SWOT Analysis
10.1.6 Sanofi Pasteur Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Basic Information
10.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 CSL
10.3.1 CSL Basic Information
10.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.3.4 CSL Business Overview
10.3.5 CSL SWOT Analysis
10.3.6 CSL Recent Developments
10.4 Abbott
10.4.1 Abbott Basic Information
10.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.4.4 Abbott Business Overview
10.4.5 Abbott Recent Developments
10.5 GlaxoSmithKline
10.5.1 GlaxoSmithKline Basic Information
10.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.5.4 GlaxoSmithKline Business Overview
10.5.5 GlaxoSmithKline Recent Developments
10.6 Serum Institute
10.6.1 Serum Institute Basic Information
10.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.6.4 Serum Institute Business Overview
10.6.5 Serum Institute Recent Developments
10.7 Fluenz Tetra
10.7.1 Fluenz Tetra Basic Information
10.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.7.4 Fluenz Tetra Business Overview
10.7.5 Fluenz Tetra Recent Developments
10.8 Cytiva
10.8.1 Cytiva Basic Information
10.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.8.4 Cytiva Business Overview
10.8.5 Cytiva Recent Developments
10.9 BioDiem
10.9.1 BioDiem Basic Information
10.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.9.4 BioDiem Business Overview
10.9.5 BioDiem Recent Developments
10.10 FluMist
10.10.1 FluMist Basic Information
10.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.10.4 FluMist Business Overview
10.10.5 FluMist Recent Developments
10.11 GSK
10.11.1 GSK Basic Information
10.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.11.4 GSK Business Overview
10.11.5 GSK Recent Developments
10.12 ChangChun High and New Technology
10.12.1 ChangChun High and New Technology Basic Information
10.12.2 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.12.3 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.12.4 ChangChun High and New Technology Business Overview
10.12.5 ChangChun High and New Technology Recent Developments
10.13 BCHT Biotechnology
10.13.1 BCHT Biotechnology Basic Information
10.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.13.4 BCHT Biotechnology Business Overview
10.13.5 BCHT Biotechnology Recent Developments
11 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET FORECAST BY REGION
11.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast
11.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region
11.2.4 South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Type (2026-2035)
12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Live Attenuated Influenza Vaccine (LAIV) by Type (2026-2035)
12.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Application (2026-2035)
12.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application
12.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)
Table 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
Table 5. Live Attenuated Influenza Vaccine (LAIV) Market Size Comparison by Region (M USD)
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2025)
Table 11. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Live Attenuated Influenza Vaccine (LAIV) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Live Attenuated Influenza Vaccine (LAIV) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (K MT)
Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)
Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Type (2020-2025)
Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2020-2025)
Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Type (2020-2025)
Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type (2020-2025)
Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Price (USD/KG) by Type (2020-2025)
Table 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Application
Table 34. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
Table 35. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025) & (K MT)
Table 36. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2020-2025)
Table 37. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application (2020-2025) & (M USD)
Table 38. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2020-2025)
Table 39. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)
Table 40. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) & (K MT)
Table 41. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2020-2025)
Table 42. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025) & (M USD)
Table 43. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025)
Table 44. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)
Table 45. North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)
Table 47. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025) & (M USD)
Table 50. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)
Table 51. South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025) & (M USD)
Table 54. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT) by Region(2020-2025)
Table 55. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2020-2025)
Table 57. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sanofi Pasteur Basic Information
Table 63. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 64. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sanofi Pasteur Business Overview
Table 66. Sanofi Pasteur SWOT Analysis
Table 67. Sanofi Pasteur Recent Developments
Table 68. AstraZeneca Basic Information
Table 69. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 70. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. AstraZeneca Business Overview
Table 72. AstraZeneca SWOT Analysis
Table 73. AstraZeneca Recent Developments
Table 74. CSL Basic Information
Table 75. CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 76. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. CSL Business Overview
Table 78. CSL SWOT Analysis
Table 79. CSL Recent Developments
Table 80. Abbott Basic Information
Table 81. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 82. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Abbott Business Overview
Table 84. Abbott Recent Developments
Table 85. GlaxoSmithKline Basic Information
Table 86. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 87. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Recent Developments
Table 90. Serum Institute Basic Information
Table 91. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 92. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Serum Institute Business Overview
Table 94. Serum Institute Recent Developments
Table 95. Fluenz Tetra Basic Information
Table 96. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 97. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Fluenz Tetra Business Overview
Table 99. Fluenz Tetra Recent Developments
Table 100. Cytiva Basic Information
Table 101. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 102. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Cytiva Business Overview
Table 104. Cytiva Recent Developments
Table 105. BioDiem Basic Information
Table 106. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 107. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. BioDiem Business Overview
Table 109. BioDiem Recent Developments
Table 110. FluMist Basic Information
Table 111. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 112. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. FluMist Business Overview
Table 114. FluMist Recent Developments
Table 115. GSK Basic Information
Table 116. GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 117. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. GSK Business Overview
Table 119. GSK Recent Developments
Table 120. ChangChun High and New Technology Basic Information
Table 121. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 122. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. ChangChun High and New Technology Business Overview
Table 124. ChangChun High and New Technology Recent Developments
Table 125. BCHT Biotechnology Basic Information
Table 126. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 127. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. BCHT Biotechnology Business Overview
Table 129. BCHT Biotechnology Recent Developments
Table 130. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2026-2035) & (K MT)
Table 131. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2026-2035) & (M USD)
Table 132. North America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)
Table 133. North America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 134. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)
Table 135. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 136. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2026-2035) & (K MT)
Table 137. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2026-2035) & (M USD)
Table 138. South America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)
Table 139. South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 140. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (Units)
Table 141. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 142. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Type (2026-2035) & (K MT)
Table 143. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2026-2035) & (M USD)
Table 144. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type (2026-2035) & (USD/KG)
Table 145. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application (2026-2035)
Table 146. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)
Table 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
Table 5. Live Attenuated Influenza Vaccine (LAIV) Market Size Comparison by Region (M USD)
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2025)
Table 11. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Live Attenuated Influenza Vaccine (LAIV) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Live Attenuated Influenza Vaccine (LAIV) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (K MT)
Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)
Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Type (2020-2025)
Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2020-2025)
Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Type (2020-2025)
Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type (2020-2025)
Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Price (USD/KG) by Type (2020-2025)
Table 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Application
Table 34. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
Table 35. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025) & (K MT)
Table 36. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2020-2025)
Table 37. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application (2020-2025) & (M USD)
Table 38. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2020-2025)
Table 39. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)
Table 40. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) & (K MT)
Table 41. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2020-2025)
Table 42. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025) & (M USD)
Table 43. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025)
Table 44. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)
Table 45. North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)
Table 47. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025) & (M USD)
Table 50. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)
Table 51. South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025) & (M USD)
Table 54. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT) by Region(2020-2025)
Table 55. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2020-2025)
Table 57. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sanofi Pasteur Basic Information
Table 63. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 64. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sanofi Pasteur Business Overview
Table 66. Sanofi Pasteur SWOT Analysis
Table 67. Sanofi Pasteur Recent Developments
Table 68. AstraZeneca Basic Information
Table 69. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 70. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. AstraZeneca Business Overview
Table 72. AstraZeneca SWOT Analysis
Table 73. AstraZeneca Recent Developments
Table 74. CSL Basic Information
Table 75. CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 76. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. CSL Business Overview
Table 78. CSL SWOT Analysis
Table 79. CSL Recent Developments
Table 80. Abbott Basic Information
Table 81. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 82. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Abbott Business Overview
Table 84. Abbott Recent Developments
Table 85. GlaxoSmithKline Basic Information
Table 86. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 87. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Recent Developments
Table 90. Serum Institute Basic Information
Table 91. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 92. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Serum Institute Business Overview
Table 94. Serum Institute Recent Developments
Table 95. Fluenz Tetra Basic Information
Table 96. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 97. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Fluenz Tetra Business Overview
Table 99. Fluenz Tetra Recent Developments
Table 100. Cytiva Basic Information
Table 101. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 102. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Cytiva Business Overview
Table 104. Cytiva Recent Developments
Table 105. BioDiem Basic Information
Table 106. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 107. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. BioDiem Business Overview
Table 109. BioDiem Recent Developments
Table 110. FluMist Basic Information
Table 111. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 112. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. FluMist Business Overview
Table 114. FluMist Recent Developments
Table 115. GSK Basic Information
Table 116. GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 117. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. GSK Business Overview
Table 119. GSK Recent Developments
Table 120. ChangChun High and New Technology Basic Information
Table 121. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 122. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. ChangChun High and New Technology Business Overview
Table 124. ChangChun High and New Technology Recent Developments
Table 125. BCHT Biotechnology Basic Information
Table 126. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 127. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. BCHT Biotechnology Business Overview
Table 129. BCHT Biotechnology Recent Developments
Table 130. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2026-2035) & (K MT)
Table 131. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2026-2035) & (M USD)
Table 132. North America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)
Table 133. North America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 134. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)
Table 135. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 136. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2026-2035) & (K MT)
Table 137. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2026-2035) & (M USD)
Table 138. South America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)
Table 139. South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 140. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (Units)
Table 141. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)
Table 142. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Type (2026-2035) & (K MT)
Table 143. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2026-2035) & (M USD)
Table 144. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type (2026-2035) & (USD/KG)
Table 145. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application (2026-2035)
Table 146. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD), 2025-2035
Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) (2020-2035)
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Product Life Cycle
Figure 13. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2025
Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2025
Figure 15. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2025
Figure 18. Industry Chain Map of Live Attenuated Influenza Vaccine (LAIV)
Figure 19. Global Live Attenuated Influenza Vaccine (LAIV) Market PEST Analysis
Figure 20. Global Live Attenuated Influenza Vaccine (LAIV) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type
Figure 27. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2020-2025)
Figure 28. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2025
Figure 29. Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2020-2025)
Figure 30. Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application
Figure 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2020-2025)
Figure 34. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application in 2025
Figure 35. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2020-2025)
Figure 36. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2025
Figure 37. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2020-2025)
Figure 39. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025)
Figure 40. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024
Figure 43. North America Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024
Figure 45. U.S. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Live Attenuated Influenza Vaccine (LAIV) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Live Attenuated Influenza Vaccine (LAIV) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024
Figure 53. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024
Figure 55. Germany Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region in 2024
Figure 68. China Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 79. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024
Figure 80. South America Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (M USD)
Figure 81. South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024
Figure 82. Brazil Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region in 2024
Figure 92. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2020-2025)
Figure 103. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 106. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Type (2026-2035)
Figure 111. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Application (2026-2035)
Figure 112. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD), 2025-2035
Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) (2020-2035)
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Product Life Cycle
Figure 13. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2025
Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2025
Figure 15. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2025
Figure 18. Industry Chain Map of Live Attenuated Influenza Vaccine (LAIV)
Figure 19. Global Live Attenuated Influenza Vaccine (LAIV) Market PEST Analysis
Figure 20. Global Live Attenuated Influenza Vaccine (LAIV) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type
Figure 27. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2020-2025)
Figure 28. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2025
Figure 29. Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2020-2025)
Figure 30. Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application
Figure 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2020-2025)
Figure 34. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application in 2025
Figure 35. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2020-2025)
Figure 36. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2025
Figure 37. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2020-2025)
Figure 39. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025)
Figure 40. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024
Figure 43. North America Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024
Figure 45. U.S. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Live Attenuated Influenza Vaccine (LAIV) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Live Attenuated Influenza Vaccine (LAIV) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024
Figure 53. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024
Figure 55. Germany Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region in 2024
Figure 68. China Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 79. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024
Figure 80. South America Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (M USD)
Figure 81. South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024
Figure 82. Brazil Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region in 2024
Figure 92. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2020-2025)
Figure 103. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 106. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Type (2026-2035)
Figure 111. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Application (2026-2035)
Figure 112. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Application (2026-2035)
